Is wine the long-sought fountain of youth?

A pharmaceutical company seems to think it may at least be the next best thing, according to this New York Times story that says British drug maker GlaxoSmithKline will plunk down $720 million in cash for shares in a company “pursuing the notion that a compound found in red wine might retard aging and let people live longer.”

That may be well and good. But something tells me they’ll have a hard time making pills taste as delicious as, say, a fruity Sangiovese.